These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15987745)

  • 1. Asymmetric dimethylarginine and kidney disease--marker or mediator?
    Vallance P; Leiper J
    J Am Soc Nephrol; 2005 Aug; 16(8):2254-6. PubMed ID: 15987745
    [No Abstract]   [Full Text] [Related]  

  • 2. Contrast-induced nephropathy and mortality: possible crucial role of asymmetric dimethylarginine.
    Andreotti F; Santucci E; Coluzzi G
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1043. PubMed ID: 18163017
    [No Abstract]   [Full Text] [Related]  

  • 3. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
    Zoccali C; Kielstein JT
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
    Vallance P; Leiper J
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide deficiency in chronic kidney disease.
    Baylis C
    Am J Physiol Renal Physiol; 2008 Jan; 294(1):F1-9. PubMed ID: 17928410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
    Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
    J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endothelium as a target in renal diseases.
    Zoccali C
    J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
    Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA
    Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Arginine--metabolism and functions in the human organism].
    Scibior D; Czeczot H
    Postepy Hig Med Dosw (Online); 2004; 58():321-32. PubMed ID: 15459550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
    Wilcken DE; Sim AS; Wang J; Wang XL
    Mol Genet Metab; 2007 Aug; 91(4):309-17; discussion 308. PubMed ID: 17560156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition.
    Zsuga J; Gesztelyi R; Török J; Kéki S; Bereczki D
    Med Hypotheses; 2005; 65(6):1091-8. PubMed ID: 16125868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
    Desai A; Zhao Y; Warren JS
    Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
    Zoccali C
    Kidney Int; 2006 Dec; 70(12):2053-5. PubMed ID: 17136131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
    Bode-Böger SM; Scalera F; Kielstein JT; Martens-Lobenhoffer J; Breithardt G; Fobker M; Reinecke H
    J Am Soc Nephrol; 2006 Apr; 17(4):1128-34. PubMed ID: 16481412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality.
    Böger RH; Maas R; Schulze F; Schwedhelm E
    Clin Chem Lab Med; 2005; 43(10):1124-9. PubMed ID: 16197309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.
    Zoccali C
    J Hypertens; 2006 Apr; 24(4):611-9. PubMed ID: 16531785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical significance of asymmetric dimethylarginine.
    Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
    Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ADMA (asymmetric dimethylarginine)--the inhibitor of nitric oxide (NO) synthesis: a new marker for vascular pathology].
    Sela BA
    Harefuah; 2005 Sep; 144(9):655-9, 675, 674. PubMed ID: 16218539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
    Fliser D
    Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.